Encouraging reports of flavonoid activity, mainly coming from in vitro or ex vivo experimental evidence, should be replicated in randomized controlled trials, to examine their ability to prevent angiopathy.
Get full access to this article
View all access options for this article.
References
1.
NguyenMMAhmannFRNagleRBRandomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities. Cancer Prev Res. 2012;5:290–8.
2.
ThomasRWilliamsMSharmaHChaudryABellamyPA double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer: the UK NCRN Pomi-T study. Prostate Cancer Prostatic Dis. 2014;17:180–6.
3.
CheungNWongIYWongTYOcular anti-VEGF therapy for diabetic retinopathy: overview of clinical efficacy and evolving applications. Diabetes Care. 2014;37:900–5.
4.
LinCHLiCHLiaoPLSilibinin inhibits VEGF secretion and age-related macular degeneration in a hypoxia-dependent manner through the PI-3 kinase/Akt/mTOR pathway. Br J Pharmacol. 2013;168:920–31.
5.
ShiXLiaoSMiHHesperidin prevents retinal and plasma abnormalities in streptozotocin-induced diabetic rats. Molecules. 2012;17:12868–81.
6.
BucoloCLeggioGMDragoFSalomoneSEriodictyol prevents early retinal and plasma abnormalities in streptozotocin-induced diabetic rats. Biochem Pharmacol. 2012;84:88–92.
7.
FanJJohnsonMHLilaMAYousefGde MejiaEGBerry and citrus phenolic compounds inhibit dipeptidyl peptidase IV: implications in diabetes management. Evid Based Complement Alternat Med. 2013;2013479505.
8.
EidenbergerTSelgMKrennhuberKInhibition of dipeptidyl peptidase activity by flavonol glycosides of guava (Psidium guajava L.): a key to the beneficial effects of guava in type II diabetes mellitus. Fitoterapia. 2013;89:74–9.
9.
PeiZFrom the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents. Curr Opin Drug Discov Devel. 2008;11:512–32.
10.
FlattPRBaileyCJGreenBDDipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. Front Biosci. 200813:3648–60.
11.
AvogaroAFadiniGPThe effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications. Diabetes Care. 2014;37:2884–94.
12.
GonçalvesAMarquesCLealEDipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats. Biochim Biophys Acta. 2014;1842:1454–63.
13.
RhoneMBasuAPhytochemicals and age-related eye diseases. Nutr Rev. 2008;66:465–72.
14.
ChiuCJTaylorANutritional antioxidants and age-related cataract and maculopathy. Exp Eye Res. 2007;84:229–45.
15.
MajumdarSSrirangamRPotential of the bioflavonoids in the prevention/treatment of ocular disorders. J Pharm Pharmacol. 2010;62:951–65.
16.
GaoZXHuangDYLiHXScutellarin promotes in vitro angiogenesis in human umbilical vein endothelial cells. Biochem Biophys Res Commun. 2010;400:151–6.
17.
ZhangKLuJMoriTBaicalin increases VEGF expression and angiogenesis by activating the ERRalpha/PGC-1alpha pathway. Cardiovasc Res. 2011;89:426–35.
18.
LiuJJHuangTSChengWFLuFJBaicalein and baicalin are potent inhibitors of angiogenesis: Inhibition of endothelial cell proliferation, migration and differentiation. Int J Cancer. 2003106:559–65.
19.
CuevasASaavedraNCavalcanteMFSalazarLAAbdallaDSIdentification of microRNAs involved in the modulation of pro-angiogenic factors in atherosclerosis by a polyphenol-rich extract from propolis. Arch Biochem Biophys. 2014;557:28–35.
20.
KumarBGuptaSKNagTCRetinal neuroprotective effects of quercetin in streptozotocin-induced diabetic rats. Exp Eye Res. 2014;125:193–202.
21.
PayneAJKajaSNaumchukYKunjukunjuNKoulenPAntioxidant drug therapy approaches for neuroprotection in chronic diseases of the retina. Int J Mol Sci. 2014;15:1865–86.
